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Discriminating between tumours and normal tissues non-inva-
sively is one of the major goals of diagnostic MR imaging.
Although tumours are often hypointense on T1-weighted images
and hyperintense on T2-weighted images compared to normal
tissues even without any contrast media, these findings are not
consistently specific. Therefore, a tumour-specific MRI contrast
agent remains important for improved detection of tumours,
staging, and their characterization. Gadolinium chelates are now
being used as the workhorse for detecting tumours in the clinical
environment. These contrast media, however, are non-specific
extravascular contrast agents. Gadolinium chelates are rapidly
delivered to tumours depending on their vascular space, and stay
in the tumour depending on the size of the extracellular compart-
ment; however in the majority of the cases, they are rapidly
washed out of the tumour. Therefore, the imaging windows for
tumour depiction using gadolinium chelates have been quite
narrow, and furthermore, the detection of hypovascular tumours
has always been problematic with non-specific agents. 
Porphyrins were the first potentially tissue-specific MR con-
trast agents to be evaluated because of their ability to form 
stable chelate complexes with paramagnetic metal ions and 
their selective retention by tumours. Moreover, complexes
containing manganese were identified as potentially the most
useful ones because of the high relaxivity of this metal. 2, 4-bis (1-
tetrahydro-fulfuroxyethyl)-deuteroporphynyl (IX)-6-7-bisaspartic
acid (THF-Mn-ASP), a prototype of HOP-9P, has shown its
tumour specific characteristics in a previous report (Suzuki et al,
1996). In this study we perform an initial evaluation of the recently
developed HOP-9P as a new tumour seeking MR contrast media
using mice in comparison to conventional gadolinium chelates. 
MATERIALS AND METHODS 
Chemicals 
The compound, 13, 17-bis (1-carboxypropionyl) carbamoylethyl-3,
8-bis (1-phenylpropyloxyethyl)-2, 7, 12, 18-tetramethyl-porphynato
manganese (III) (HOP-9P) has a molecular weight of 1135. In this
study, HOP-9P was dissolved with 0.1 M phosphate buffer
(pH8.0), and gadolinium-diethylenetriaminepentaacetic acid (Gd-
DTPA) (Magnevist, Nihon Schering, Co. Ltd) was diluted with
physiological saline before use. 
Phantom study for relaxivity measurements 
The relaxivity of HOP-9P was measured at 37˚C in 0.9% sodium
chloride solution in a 50 ml polypropylene centrifuge tube using a
1.5T super-conductive imager (Magnetom SP, Siemens Medical
Systems, Erlangen, Germany). Relaxivity of Gd-DTPA was also
measured for comparison. The T1 relaxation times for each 
solutions were calculated using the spin echo sequence (SE) (TR 
of 400 and 2400 ms), with 15 ms of TE. A matrix of 256 ´ 256 
and slice thickness of 8 mm were used for the T1 measurements.
Five different concentrations 1 M, 0.5 M, 0.25 M, 0.125 M, and 
0.0625 M were prepared both for HOP-9P and Gd-DTPA solution
for relaxivity plotting. 
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the tumour, muscle, liver, blood and kidneys was measured using optical emission spectrometers and was expressed as micrograms of
manganese per gram of tissue. The tumour/muscle signal intensity ratio at 24 h (3.18 ± 0.34) was significantly higher than precontrast ratio
(1.77 ± 0.20) (P < 0.05). The biodistribution assessment of manganese demonstrated that HOP-9P gradually and consistently accumulated in
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Tumour model 
SCC VII squamous cell carcinomas derived from C3H mice are
maintained in Eagle’s minimum essential medium. Approximately
1.0 ´ 106 cells were inoculated subcutaneously into the right flank
of 6-week-old male C3H/He mice (SLC., Co. Ltd Shizuoka,
Japan). Fourteen days after the inoculation, mice bearing tumour
with 1–3 cm in diameter were used in this experiment. All proce-
dures involving animals were carried out in accordance with the
regulations for animal welfare in the university. 
In vivo MR imaging 
Seven mice were used for HOP-9P enhanced MR imaging, and
five mice were used for Gd-DTPA enhanced imaging. 1.5T super-
conductive imager (Signa Horizon Echospeed, GE Medical
systems, WI, USA) together with a 5-inch surface coil was used
for imaging. Under general anesthesia induced by an intraperi-
toneal injection of pentobarbital (30–50 mg/kg), T1-weighted
conventional images and T2-weighted fast spin echo images were
acquired before contrast administration. T1-weighted spin echo
imaging was repeated 5 min, 2 h and 24 h after intravenous injec-
tion of HOP-9P, and 5 min, 30 min, 1 h and 2 h after administra-
tion of Gd-DTPA. Parameters used for T1 weighted imaging 
were TR (ms)/TE (msec) of 500/35, a field of view (FOV) (cm) of
12 ´ 12, NEX of 1, image matrix of 256 ´ 128, and slice thickness
of 3 mm. Coronal interleave scan was performed in 2 min and 
24 s. For coronal T2 weighted imaging, TR (ms)/TE (ms) of 2000/90,
echo train length of 8, FOV (cm) of 12 ´ 12, NEX of 1, image matrix
of 256 ´ 128, slice thickness of 3 mm and slice gap of 3 mm were
used. The imaging time for the T2 weighted imaging was one
minute and 12 s. 0.1 mmol/kg (0.01 ml/g) of either of HOP-9P or
Gd-DTPA was injected into the lateral tail vein of the mice. A
water phantom and an oil phantom were also included in the FOV. 
Quantitative image analysis 
On a network computer, mean signal intensities were measured by
focusing circular regions of interest on the tumour, muscle and oil
phantom. Tumour/oil signal intensity ratio (SIR) and tumor/
muscle SIR were then calculated. 
Biodistribution analysis 
Nineteen mice were sacrificed by cervical dislocation 5 min, 2 h
and 24 h after the administration of HOP-9P. Eleven mice were
sacrificed in the same manner after Gd-DTPA injection. In addi-
tion, eight mice were used for control study. Manganese and
gadolinium concentrations in the blood, tumor, muscle, liver and
kidneys were quantified using optical emission spectrometers
(SPS 1200A, Seiko Instruments Inc., Chiba, Japan) with induc-
tively coupled argon plasma (ICAP), and were expressed as mg of
manganese or gadolinium per gram of tissue. The wavelengths
used for measurements were 342.247 nm for gadolinium and
257.610 nm for manganese. 
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Figure 1 Spin lattice relaxation rates (1/T1) of water at 1.5T as a function of
concentration (M) of two contrast media; Gd-DTPA (line with circular marks)
and HOP-9P (line with triangular marks). The relaxivity of HOP-9P is about
four-fold compared to that of Gd-DTPA
AB C D
Figure 2 Representative MR images acquired pre- and post-HOP-9P injection (0.1 mmol/kg). Repeated acquisitions of T1 weighted images with use of spin
echo sequence (TR/TE: 500/35). Precontrast (A), 5 min (B), 2 h (C) and 24 h (D) after contrast injection. Note progressive and marked enhancement of the
tumour in the right flank Statistical analysis 
Data are expressed as means ± SD. Differences between SI values
obtained before and after administration of contrast material
within each group were evaluated with a repeated-measure
analysis of variance followed by the Fisher’s PLSD test.
Differences of metal concentrations between pre-enhancement and
post-enhancement for tumour and other organs were analysed
using a Student’s t-test, where Bartlett’s test indicated homo-
geneity of variance, or by a non-parametric Mann-Whitney test. 
P < 0.05 was accepted as statistically significant. 
RESULTS 
A linear correlation between the concentration of the paramagnetic
agents and longitudinal relaxivity was found. The relaxivity of
HOP-9P was consistently stronger than Gd-DTPA (Figure 1). 
MR images demonstrated significant enhancement of trans-
planted tumour after intravenous injection of HOP-9P (Figure 2).
Time course changes in ratio of SI of tumour/oil and
tumour/muscle are shown in Table 1. The tumour/oil SIR peaked
at 24 h (0.75 ± 0.17) compared to precontrast ratio (0.36 ± 0.03)
(P < 0.05). The tumour/muscle SIR was highest at 24 h (3.18 ±
0.34) compared to precontrast ratio (1.77 ± 0.20) (P < 0.05). Mean
percent increase in signal intensity at 24 h was 124% in the
tumour/oil ratio and 79% in tumour/muscle ratio. The concentra-
tion of manganese after 0.1 mmol/kg HOP-9P injection in the
blood was 24.7 ± 2.47 m gMn/g tissue at 5 min. HOP-9P rapidly
distributed to the liver and kidneys, and afterward, it was gradually
washed out of or excreted from the organs. Tumours showed
gradual and selective retention of the metal complex with the
highest value of 3.49 ± 1.22 mg Mn/g reached at 24 h following
intravenous administration (Table 1). The metal concentration in
tumors remained consistently higher than muscle both at 2 h and
24 h and a three- to four-fold increase in tumour/muscle concentra-
tion ratio over the control was seen at 24 h. 
Tumour enhancement was recognized in mice receiving Gd-
DTPA at 5 min after contrast injection, however it faded out there-
after (Figure 3). Tumour conspicuity on the images increased by
30% in tumour/oil ratio and 19% in tumour/muscle ratio, at 5 min
and then decreased. Gadolinium concentration in the tumor was
similar to that in the bloodstream with the highest concentration of
10.3 ± 1.74 m gGd/g at 5 min after contrast injection. Two hours
after Gd-DTPA injection, gadolinium was virtually washed out
from the tumor with a tissue concentration of 0.38 ± 0.28 mg Gd/g
(Table 1). 
DISCUSSION 
Since an initial investigation by Chen et al, metalloporphyrin
derivatives using manganese have been studied by several groups
and shown to significantly enhance the conspicuity of a number of
murine tumours and human tumour xenografts in murine hosts
(Chen et al, 1984). These studies were generally undertaken with
the objective of developing tumour-specific paramagnetic contrast
enhancing agents. Enhancement of the MRI signal from tumour
has been known to correlate with a high concentration of metallo-
porphyrins in tumor tissue. The uptake of porphyrins by tumours is
not fully understood, but may include selective transport and
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Figure 3 Representative MR images obtained before (A) and after (B and C) intravenous administration of Gd-DTPA (0.1 mmol/kg). The tumour in the right
flank is moderately enhanced 5 min after the injection. The lesion conspicuity after contrast injection, however, is less than that acquired with HOP-9P. The
tumour enhancement faded out 2 h after injection (C). passive diffusion. It is said that hydrophilic agents distribute into
extracellular stroma, whereas hydrophobic compounds show intra-
cellular distribution (Megnin et al, 1987; Oenbrink et al, 1988).
Several hypotheses have been proposed concerning this high
concentration of metalloporphyrins in the tumour. First, a combi-
nation of high capillary permeability and the lack of lymphatic
drainage in the neoplasm may result in the stasis of porphyrin.
Second, porphyrins have strong affinities to stromal elements such
as highly concentrated collagenous tissues found in the large inter-
stitial space of tumors (Jain, 1987; Kessel et al, 1983). Third, some
metalloporphyrin derivatives have high affinity for low-density
lipoprotein (LDL), and the uptake is dependent on the lipophilic
feature of them. It is generally accepted that in neoplastic cells,
LDL receptor distribution is markedly increased (Dagan et al,
1995; Niendorf et al, 1995). Lipophilic porphyrins may be taken
into the cancer cells via LDL receptor pathways (Fiel et al, 1988;
Kessel et al, 1983; Nakajima et al, 1995; Reyftmann et al, 1984;
Takemura et al, 1994). Lastly, some of the water-soluble
porphyrins may be bound to a b-glycoprotein such as haemopexin
that is structurally similar to hyaluronidase (Nakajima et al, 2000;
Zhu et al, 1994). Hyaluronidase is an enzyme involved in tumour
proliferation and metastasis as well as in neovascularization. Some
of the water-soluble porphyrins may be carried into tumours by
haemopexin (Nakajima et al, 2000). 
This study has revealed that HOP-9P, similar to other Mn-
porphyrins, causes effective and potent shortening of T1 value not
only in vitro (a four-fold relaxivity compared to Gd-DTPA), but
also in vivo. Koenig et al had previously discussed the mechanism
of this unusually high relaxivity of Mn-porphyrins. They
suggested the effect may be mainly due to the anisotropy of the
ground-state wave function of Mn3+ in the porphyrin complex,
effectively bringing the spin density of the Mn3+ ions closer to the
protons of the coordinated water molecules (Koenig et al, 1987).
This effect is favourable for use as contrast agents, because a high
relaxivity can reduce the dosage required to achieve a given en-
hancement of contrast in MRI, thereby reducing the risk of 
toxicity (Koenig et al, 1987). 
Mn-porphyrin HOP-9P was distributed in the circulation system
rapidly during the first 5 min and therefore, the concentration of
HOP-9P in the muscle was initially high. This resulted in low
tumour/muscle contrast shown on the images at 5 min. However,
HOP-9P was rapidly removed from the muscle likely due to back
diffusion into the circulation system, and accumulated by the
tumour gradually and consistently. This resulted in an increase in
contrast between the tumour and muscle on the MR imaging at 2 h
and 24 h. Tumour enhancement was much improved by HOP-9P
in comparison to the prototype THF-Mn-ASP. The maximum
increase of tumour/muscle intensity ratio was 32% using 
THF-Mn-ASP (Suzuki et al, 1996), whereas a 79% increase was
observed in this study with HOP-9P with the same dose in mice. 
As a tool for diagnostic imaging strategy, HOP-9P has unique
characteristics for tumour detection. Unlike non-specific extravas-
cular contrast media such as Gd-DTPA, the imaging window for
detection of neoplasm with HOP-9P is much wider. In this study,
we employed conventional spin echo sequence and normal
contrast injection strategies in acquiring enhanced T1 weighted
images, which required 2 min and 24 s. Based on the clinical expe-
riences, however, optimum-imaging timing after Gd- DTPA injec-
tion is the first pass of the contrast, which is within 1 min. Yet, in
our study, it was not practical to accomplish bolus injection of the
contrast media inside the magnet. Typically, in the clinical setting,
combined use of fast MR imager equipped with high performance
gradient system and a power injector for bolus injection of the
contrast media are necessary. Unlike Gd-DTPA, HOP-9P may not
require the state-of-the-art equipment and strategies. A conven-
tional MR system with lower Tesla magnet with ordinary contrast
infusion will likely enable sufficient tumour discriminations. 
Aside from diagnostic usage, porphyrin derivatives have also
been developed as an agent for photodynamic therapy (Calzavara-
Pinton et al, 1996; Hill et al, 1996; Kessel, 1992; Kostenich et al,
1997; Lapes et al, 1996; McIlroy et al, 1998; Nakajima et al, 1998;
Shopova et al, 1994; Takemura et al, 1992; Woodburn et al, 1998),
radiation sensitizer (Rowinsky 1999; Viala et al, 1999) and an
agent for neutron capture therapy (Matsumura et al, 1999; Miura 
et al, 1996; Shibata et al, 1998). This study revealed that the
enhancement effect of the tumour demonstrated on the MR images
was well correlated with the biodistribution of the HOP-9P (Figure 2,
Table 1). MR imaging using HOP-9P might be a safe and useful 
tool for predicting the effectiveness of the photodynamic therapy
and radiation therapy including neutron capture. It may also be
used to evaluate the outcome of those therapeutic procedures. 
THF-Mn-ASP, a prototype of HOP-9P, has an LD50 of more
than 2000 mg/kg in mice (Kobayashi et al, 1999), and HOP-9P has
no known phototoxicity. Given these characteristics, HOP-9P may
be a safe compound for MR imaging. 
Although a detailed study of the pharmacokinetics and toxi-
cology of this agent is needed before its usefulness as tumour-
specific contrast media is fully established, current biodistribution
analysis and the imaging study have suggested that HOP-9P is a
potentially tumour specific contrast media in an animal model. 
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